Mar 16, 2022 / 02:45PM GMT
Balaji V. Prasad - Barclays Bank PLC, Research Division - Director
Good morning, everyone. Welcome to Day 2 of the Barclays Healthcare Conference. Continuing the [spectrum] track for the day, I'm delighted to have the management of Viatris with me. Just like what the slide says, we have Mike Goettler, the CEO of Viatris with us; and Rajiv Malik, President; and Sanjeev Narula, the CFO.
Questions and Answers:
Balaji V. Prasad - Barclays Bank PLC, Research Division - DirectorSo starting with -- this is going to be a fireside comment -- fireside chat format. And really since the last 15 days, Mike and Rajiv, Sanjeev, in further discussions, right, think -- I don't think you would have expected the reaction to your announcement, the way the stock has reacted. Investors are understandably in angst. So let's speak about capital allocation. Basically, what do you think about the biosimilars business and exiting the business and then investing in the newer assets, which is asset undisclosed or newer areas? And how do you think competitors, in terms of, like, the
Trustpilot
